ADAPTIMMUNE
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.
ADAPTIMMUNE
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2008-01-01
Address:
Oxton, York, United Kingdom
Country:
United Kingdom
Website Url:
http://www.adaptimmune.com
Total Employee:
501+
Status:
Active
Contact:
+1 (215) 825 9260
Total Funding:
499.5 M USD
Technology used in webpage:
Domain Not Resolving IPv6 ReCAPTCHA Nginx ReCAPTCHA V2 DoubleClick.Net Microsoft Google Adsense Mobile Optimized New Relic
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Agenus
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Healx
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Kuros Biosciences
Kuros Biosurgery develops biomaterials and bioactive biomaterial combination products for indications in trauma, wound and spine.
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Theravectys
Theravectys develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2023-03-06 | TCR2 | TCR2 acquired by Adaptimmune | N/A |
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Adaptimmune
Genentech
Genentech investment in Post-IPO Equity - Adaptimmune
Eight Roads Ventures
Eight Roads Ventures investment in Venture Round - Adaptimmune
Merlin Nexus
Merlin Nexus investment in Series A - Adaptimmune
F-Prime Capital
F-Prime Capital investment in Series A - Adaptimmune
Wellington Management
Wellington Management investment in Series A - Adaptimmune
Ridgeback Capital
Ridgeback Capital investment in Series A - Adaptimmune
University of Oxford
University of Oxford investment in Series A - Adaptimmune
Foresite Capital
Foresite Capital investment in Series A - Adaptimmune
Novo Holdings
Novo Holdings investment in Series A - Adaptimmune
Key Employee Changes
Official Site Inspections
http://www.adaptimmune.com Semrush global rank: 1.47 M Semrush visits lastest month: 16.99 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Adaptimmune"
Adaptimmune - Wikipedia
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University …See details»
Our Company :: Adaptimmune (ADAP)
Adaptimmune embraces this personalized approach from discovery through delivery with fully integrated capabilities including research, global clinical development, translational sciences, commercialization, and manufacturing.See details»
Leadership Team :: Adaptimmune (ADAP)
In this role, she built the Allogeneic Research organization from the ground up and took the concept of iPSC-derived allogeneic T-cell therapies from an idea into the potential for an allogeneic candidate in the clinic. Prior to her SVP role, Dr. …See details»
Adaptimmune - Crunchbase Company Profile & Funding
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a …See details»
Adaptimmune Information - RocketReach
Adaptimmune is a fully integrated cell therapy company, designed and built from the ground up with four U.K.- and U.S.-based biotechnology hub locations. Our comprehensive capabilities …See details»
Adaptimmune - LinkedIn
Adaptimmune is a fully integrated cell therapy company, designed and built from the ground up with four U.K.- and U.S.-based biotechnology hub locations.See details»
Adaptimmune - LinkedIn
Adaptimmune | 50,393 followers on LinkedIn. Designing and delivering cell therapies to transform the lives of people with cancer. | Adaptimmune is a fully integrated cell therapy company, …See details»
Adaptimmune - Company Profile - Tracxn
Dec 7, 2024 What are the most recent funding rounds of Adaptimmune? Its latest funding round was a Series A round on Sep 24, 2014 for $104M. 12 investors participated in its latest round, …See details»
Adaptimmune Company Profile - Office Locations, Competitors
Oct 29, 2024 Adaptimmune has 4 employees across 4 locations and $60.28 m in annual revenue in FY 2023. See insights on Adaptimmune including office locations, competitors, …See details»
Adaptimmune LLC | Life Sciences PA - Default Site
Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell …See details»
Company Information :: Adaptimmune (ADAP)
Adaptimmune is a leader in TCR T-cell therapy, focused on designing and delivering novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and …See details»
Member profile: Adaptimmune Ltd | BIA - bioindustry.org
Adaptimmune, a leader in cell therapy, is a late-stage biopharmaceutical company, with a pipeline of therapies in clinical trials in 10 solid tumors. About Adaptimmune Ltd Adaptimmune, a …See details»
Adaptimmune - Contacts, Employees, Board Members, Advisors
Organization. Adaptimmune . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... About. Adaptimmune has 13 current …See details»
New Executive Team Announced at Adaptimmune
Adaptimmune Contacts: Media Relations: Sébastien Desprez – VP, Communications and Investor Relations T: +44 1235 430 583 M: +44 7718 453 176 [email protected] …See details»
Our Company - Adaptimmune (ADAP)
Adaptimmune at a Glance. More About Adaptimmune. Manufacturing at Adaptimmune . Our Research: A Rich Cell Therapy Pipeline for the Future . 39th Annual J.P. Morgan Healthcare …See details»
Adaptimmune CEO and Key Executive Team | Craft.co
Adaptimmune's Chairman is David M. Mott. Other executives include Gavin Wood, Chief Financial Officer; Lawrence M. Alleva, Non-Executive Director and 7 others. See the full leadership team …See details»
Adaptimmune Q&A: an alternative approach to T-cell cancer …
Sep 20, 2021 DJ: What advantages does Adaptimmune’s approach have over CAR T-cell cancer therapies? HTM: One of the key distinctions between a T-cell receptor-based approach …See details»
21: Adaptive Immunity I - Biology LibreTexts
21.1: Adaptive Immune Defenses - Overview Adaptive immunity is defined by two important characteristics: specificity and memory. Specificity refers to the adaptive immune system’s …See details»
Corporate Presentations :: Adaptimmune (ADAP)
Latest Corporate Deck. Nov 21, 2024. Adaptimmune Corporate Deck November 2024See details»
Clinical Trials - Adaptimmune (ADAP)
SPEARHEAD-1 (afamitresgene autoleucel ‘afami-cel’; formerly ADP-A2M4) This is a Phase 2, open-label, single arm clinical trial to evaluate the anti-tumor activity of afami-cel T-cells in …See details»